Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progressive forms of MS: classification streamlined or consensus overturned?

B G Weinshenker1

  • 1Department of Neurology, Mayo Clinic/Mayo Foundation, Rochester, MN 55902, USA.

Lancet (London, England)
|February 16, 2000
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of MOG antibody associated disorders: results of an international survey.

Journal of neurology·2020
Same author

Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up.

Journal of neurology, neurosurgery, and psychiatry·2019
Same author

[MOG encephalomyelitis: international recommendations on diagnosis and antibody testing].

Der Nervenarzt·2018
Same author

MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.

Journal of neuroinflammation·2018
Same author

A population-based prospective study of optic neuritis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2017
Same author

Stopping immunomodulatory medications in MS: Frequency, reasons and consequences.

Multiple sclerosis and related disorders·2015
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
See all related articles